Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
European Journal of Cancer (Oxford, England : 1990)|July 3, 2007
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology groupSabine Maier, Inko Nimmrich, Thomas Koenig, et al.
British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.
JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trialMonika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
Breast Care (Basel, Switzerland)|March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPTMichael Braun, Oleg Gluz, Sherko Kuemmel, et al.
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.
Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Pageof 5